CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses

Etude concernée: IFCT-1401
Auteurs / Authors: G. Goss, G. Darling, V. Westeel, K. Nakagawa, B. Massuti Sureda, F. Perrone, S. McLachlan, J.H. Kang, Y. Wu, A.C. Dingemans, R. Dziadziuszko, M. Okada, L. Greillier, C. Audigier-Valette, S. Sugawara, E. Nadal, A. Catino, M.R. Stockler, K.U. Ding, C. O'Callaghan
Journal / Conference: ESMO
Année / Year: 2025
PMID: Oral abstract
Lien vers la publication: https://clin.larvol.com/abstract-detail/ESMO%202025/77184832